NON-SMALL-CELL LUNG CANCER

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This early-phase trial is testing a new RNA vaccine called IMP3-saRNA (YMN-136) in 9 people with advanced non-small cell lung cancer who have run out of standard options. The vaccine aims to train the immune system to attack cancer cells that carry a specific marker (IMP3). The m…

This study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial tests a new type of immunotherapy where a patient's own T cells are genetically engineered to recognize and attack cancer cells with a specific KRAS G12D mutation. The study includes adults with advanced lung, colorectal, pancreatic, or endometrial cancers …

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults will take part across 10 countries. The study is open to those with a speci…

This study provides ongoing treatment with the cancer drug adagrasib (BMS-986503) to patients with advanced solid tumors who have already seen benefit in earlier studies. About 170 adults with non-small cell lung cancer, colorectal cancer, or other solid tumors can join if they a…

This study tests a new drug, BNT327, combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. The trial will enroll about 1,260 participants across multiple sites worldwide. The goal is to see if the combinat…

This study tests a new drug called STK-012, which is designed to boost the immune system's ability to fight cancer. It is being tested alone or with standard treatments (pembrolizumab, pemetrexed, carboplatin) in people with advanced solid tumors, especially those with a type of …

This Phase 3 trial tests whether adding a maintenance drug (sacituzumab tirumotecan) after initial chemo-immunotherapy improves survival in people with metastatic squamous non-small cell lung cancer. About 851 participants will receive pembrolizumab plus chemotherapy, then either…

This phase 2 trial is testing three different doses of an investigational drug called telisotuzumab vedotin in about 150 adults with a specific type of advanced lung cancer (non-small cell lung cancer that has high levels of a protein called c-Met and no EGFR mutation). The drug …

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can help prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and imm…

This early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This phase 3 trial tests TAK-928, a drug designed to activate T cells inside tumors, against standard chemotherapy (docetaxel) in 600 adults with advanced non-small cell lung cancer that has worsened after prior treatments. The goal is to see if TAK-928 can shrink tumors or help …

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This Phase 3 trial is testing whether adding an experimental drug called calderasib (MK-1084) to standard immunotherapy (pembrolizumab) can keep non-small cell lung cancer from returning after surgery. The study enrolls 400 people with a specific KRAS G12C mutation whose cancer w…

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can eliminate all signs of cancer in people with resectable stage II to IIIB non-small cell lung cancer. About 60 participants will receive the comb…

This phase 3 trial tests whether adding the targeted pill calderasib (MK-1084) to the immunotherapy durvalumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 310 participants who have finished chemotherapy and radiation …

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This study tests whether a special radiation method (SFRT) given alongside immunotherapy (tislelizumab) and standard chemotherapy can shrink stage III lung tumors that cannot be surgically removed. The goal is to see if this combination makes more patients eligible for surgery. T…

This early-phase trial tests a new drug called BI-1206, given alongside the immunotherapy pembrolizumab, in adults with advanced solid tumors that have stopped responding to prior anti-PD-1/PD-L1 treatment. The study aims to find the safest dose and check for early signs of tumor…

This program offers early access to the investigational drug neladalkib for people with advanced ALK-positive lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at least 18 years old…

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This study tests several drug combinations given before and after surgery for early-stage non-small cell lung cancer. About 630 participants will receive immunotherapy drugs like durvalumab along with chemotherapy or other targeted agents. The goal is to see if these combos can e…

This phase 3 trial is testing whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of…

This early-phase trial is testing a new drug called BMS-986517 in about 315 adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to check the drug's safety and find the right dose. Researchers will also look for signs that the drug …

This early-stage study tests a new drug called azirkitug, alone or with other cancer medicines, in people with advanced solid tumors like lung, head/neck, and pancreatic cancers. The goal is to find safe doses and check side effects. About 694 adults will take part worldwide, rec…

This study tests an experimental mRNA therapy called mRNA-4359, given alone or with standard immunotherapy drugs, in people with advanced solid tumors (like melanoma, lung cancer, or colorectal cancer). The main goals are to find a safe dose and see if the treatment can shrink tu…

This study tests whether adding electro-acupuncture to standard first-line treatment (PD-1 inhibitors plus chemotherapy) helps people with metastatic non-small cell lung cancer. About 424 participants will receive either real or sham acupuncture alongside their cancer therapy. Th…

This Phase 3 trial is testing a new oral drug called daraxonrasib (RMC-6236) against the standard chemotherapy docetaxel in about 590 people with advanced non-small cell lung cancer that has a specific RAS mutation. Participants must have already tried at least one prior treatmen…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This phase 3 trial tests whether the immunotherapy drug cemiplimab can prevent lung cancer from returning after surgery in patients with stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors have PD-L1 levels of 1% or higher. About 390 participants will either receive cem…

This study tests a new drug called izalontamab brengitecan against standard chemotherapy in 500 people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to current targeted pills. The goal is to see if the new drug can delay…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific KRAS G12D mutation, including pancreatic, lung, and colorectal cancers. The main goals are to check safety and see if the drug shrinks tumors, given alone or with chemoth…

This study tests whether taking pentoxifylline and vitamin E during chemoradiation can prevent lung injury (pneumonitis) in stage III non-small cell lung cancer patients. 150 participants will receive either the drug combo or a placebo for 6 months. The goal is to see if this red…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-stage trial is testing a new radioactive drug (177Lu-DFC413) to see if it is safe and can shrink tumors in people with advanced solid cancers like pancreatic, lung, breast, colorectal, and sarcoma. About 180 adults whose cancer has progressed after standard treatments …

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This study tests whether combining two drugs, YL201 and ivonescimab, can safely shrink tumors in people with advanced solid cancers, including lung cancer. About 260 adults whose cancer has not responded to other treatments will receive the combination. The goal is to find the be…

This trial investigates whether combining two targeted drugs, vebreltinib and furmonertinib, can control advanced non-small cell lung cancer in people whose tumors have both an EGFR mutation and high PD-L1 expression. The study enrolls about 45 adults who have not received prior …

This study tests a lower-dose radiation regimen for people with non-small cell lung cancer located near the center of the chest. The goal is to see if giving a total of 45 Gray in three sessions can control the tumor while reducing damage to nearby organs like the heart and major…

This phase 2 trial tests a combination of two drugs, ABSK043 and glecirasib, in people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The study will enroll 86 participants to see if the combination is safe and can shrink tumors. It i…

This study tests whether a focused ultrasound device can safely open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. About 30 participants will receive standard immunotherapy plus the ultrasound procedure. The goal is to see if this…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This phase 2 trial is testing whether adding two immunotherapy drugs, IPH5201 and durvalumab, to standard chemotherapy before and after surgery can improve outcomes for people with early-stage (stage II to III) non-small cell lung cancer. The study includes two groups: one receiv…

This phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …

This early-stage trial is testing a new drug called IM-1617 in people with advanced solid tumors (cancers that have spread or can't be removed by surgery). The study has two parts: first, finding a safe dose, then testing that dose in more people to see how well it works and how …

This Phase 2 trial is testing whether using two immune therapy drugs together with chemotherapy works better than one immune drug plus chemo for people with advanced non-small cell lung cancer that lacks the PD-L1 marker. Researchers will track changes in tumor DNA in the blood t…

This study compares a new drug, YL202, with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific EGFR mutation. Participants must have already tried an EGFR-targeted therapy and platinum chemo without success. The goal is to s…

This study tests whether adding targeted radiation to immunotherapy can help control advanced non-small cell lung cancer better than standard chemotherapy. It is for patients whose cancer has worsened after previous immunotherapy. About 39 adults will be randomly assigned to one …

This study tests whether adding focused radiation or ablation to standard drug therapy can help people with lung cancer that has only a few new spots of growth. The goal is to see if this approach allows patients to stay on their current treatment longer without needing to switch…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from coming back in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. All participants have had surgery to remove their tumor and standard che…

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This expanded access program provides the investigational drug zidesamtinib (NVL-520) to adults with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have no satisfactory treatment options and cannot join a clinical trial. Participants must have receive…

This Phase 3 trial is testing whether a combination of two drugs, datopotamab deruxtecan (Dato-DXd) and rilvegostomig, works better than the current standard treatment pembrolizumab for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 participan…

This study tests a drug called divarasib, either alone or with other cancer treatments, in people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and works to shrink or control the cancer. About 320 people who have …

This Phase 3 trial tests whether adding the targeted drug calderasib to the immunotherapy pembrolizumab helps people with a specific KRAS G12C-mutated lung cancer live longer without their cancer growing. About 675 participants with advanced non-squamous non-small cell lung cance…

This study tests whether combining two drugs, tepotinib and ivonescimab, is safe and works for people with advanced non-small cell lung cancer that has a specific genetic change called METex14 skipping. About 16 participants will try different doses to find the one with the fewes…

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This early-phase study tests an experimental drug called OKN4395, taken as a pill, alone or together with the immunotherapy pembrolizumab. The goal is to find a safe dose and see if the combination can shrink tumors in people with advanced solid cancers like lung, colorectal, sto…

This phase 2 trial is testing whether combining three anti-cancer drugs—carboplatin, paclitaxel, and ramucirumab—can shrink tumors or slow their growth in people with advanced non-squamous non-small cell lung cancer. The study enrolls adults whose cancer has progressed after at l…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This phase 3 study compares two immunotherapy drugs—rilvegostomig and pembrolizumab (Keytruda)—each combined with standard chemotherapy, as a first treatment for people with advanced squamous non-small cell lung cancer that has a specific protein (PD-L1). About 880 participants w…

This program provides early access to the experimental drug zipalertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. It is for those who have no other good treatment …

This phase 3 trial compares a new targeted drug, telisotuzumab vedotin, to the standard chemotherapy docetaxel in adults with a specific type of advanced non-small cell lung cancer that has a high level of a protein called c-Met. About 698 participants worldwide will receive eith…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…

This phase 3 trial tests whether a personalized mRNA cancer vaccine (intismeran) alone or combined with an immunotherapy drug (pembrolizumab) can prevent non-small cell lung cancer from coming back after complete surgical removal. About 876 people with high-risk stage I lung canc…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't grown after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the combo …

This study tests a new treatment using specially engineered natural killer (NK) cells to attack advanced lung cancer that has spread. About 60 adults whose tumors have certain markers will receive chemotherapy followed by an infusion of these cells. The goal is to find a safe dos…

This study tests whether adding the investigational drug NKTR-255 to the standard immunotherapy durvalumab can help restore immune cells after chemoradiation in people with advanced non-small cell lung cancer. About 39 adults will receive the combination and be followed for overa…

This study is testing a new treatment model for elderly patients (65+) with early-stage lung cancer. It combines advanced surgical techniques, personalized care before and after surgery, and rehabilitation programs. The goal is to improve survival and reduce complications. Resear…

This phase 2 trial tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers, including breast, lung, stomach, and others. Participants have already tried at least one standard treatment. The study measures how many tumors shrink or disappear. Zanida…

This study tests whether a new drug (divarasib) combined with immunotherapy (pembrolizumab) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 600 adults who have not had…

This study tests different drug combinations in people with early-stage non-small cell lung cancer that can be removed with surgery. The drugs are chosen based on specific genetic markers in each person's tumor. The goal is to see if these treatments shrink the tumor before surge…

This study tests whether adding targeted radiotherapy (SBRT) to standard drug therapy can slow or stop lung cancer from growing in people with metastatic non-small cell lung cancer. About 320 participants whose cancer has started to progress on first-line treatment will receive e…

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This study tests whether a simple blood test that measures cancer DNA (ctDNA) can help doctors decide when to add chemotherapy to the standard immunotherapy drug pembrolizumab for people with advanced lung cancer. About 230 participants will be enrolled. The goal is to see if thi…

This study tests a new medicine called PF-08634404, given alone or with chemotherapy, for adults with early or locally advanced non-small cell lung cancer. The trial has three parts: before surgery, after surgery if cancer remains, or after chemoradiation. Researchers will check …

This study tests whether a new experimental drug called PF-08634404, given with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to rec…

This study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…

This phase II trial tests two drugs—HLX43 and serplulimab—given before surgery to people with stage II-IIIB non-small cell lung cancer. The goal is to see if the combination can reduce tumor size, making surgery more effective. About 60 participants will be enrolled to evaluate s…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This early-phase study tests a virus (JNJ-87704916) that is injected directly into tumors to kill cancer cells. It is being tested alone and with another drug (cetrelimab) in people with advanced solid tumors who have run out of standard treatments. The main goals are to check sa…

This early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…

This study is for people with advanced non-small cell lung cancer who are not well enough for standard strong chemotherapy. It tests a combination of one chemotherapy drug and an immunotherapy drug (pembrolizumab) to see if it is safe and helps shrink tumors. About 60 participant…

This study tests a new experimental drug called PF-08634404 combined with other cancer medicines in people with advanced non-small cell lung cancer that has spread and can't be surgically removed. The trial has two parts: one combining PF-08634404 with sigvotatug vedotin, and ano…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This study tests a new approach for people with advanced lung cancer whose disease got worse after initial treatment. It combines an injected virus (Olvi-Vec) that targets cancer cells, followed by chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy a…

This study tests a new drug called Ivonescimab for people with non-small cell lung cancer who need surgery. The drug is given before surgery to shrink tumors and make them easier to remove. The study compares Ivonescimab to standard treatments and looks at how well it works and w…

This early-phase study tests a new drug called BBO-11818 in people with advanced cancers that have a KRAS mutation, including lung, pancreatic, and colorectal cancers. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. Abou…

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This study tests whether a lower dose of chemotherapy combined with an immunotherapy drug can be a safer and still effective first treatment for older adults (70+) or those who are frail with advanced non-small cell lung cancer. The main goal is to see if fewer people have to sto…

This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. Abou…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This phase 3 study compares a new drug, NVL-655, to the standard treatment alectinib in people with advanced ALK-positive non-small cell lung cancer who have not had prior therapy. About 450 participants will be randomly assigned to receive either NVL-655 or alectinib. The main g…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study is for people with advanced EGFR-mutated non-small cell lung cancer whose cancer still shows signs of activity (detected by a blood test) after taking the drug osimertinib alone. The trial will test whether adding a second drug, sacituzumab tirumotecan, can improve out…

This phase 2 trial is testing whether adding a targeted drug called HER3-DXd to standard immunotherapy (pembrolizumab) and chemotherapy can help people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different combinations…

This study tests a new combination of two oral drugs, DZD6008 and sunvozertinib, in 160 adults with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to check safety, how the drugs move through the body, and whether they shrink tumors. It is the fir…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests a drug called DRP-104 in people with advanced non-small cell lung cancer that has specific gene changes (NFE2L2 or KEAP1). The drug works by blocking glutamine, a nutrient cancer cells need to grow. The trial aims to see if the drug can shrink tumors or slow the …

This early-stage trial is testing a new drug that delivers a tiny amount of radiation directly to cancer cells. It is for people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The study will check if the drug is…

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests whether lower doses of chemotherapy can effectively control lung cancer in patients aged 70+ or those with other health problems. About 280 participants will receive pre-set reduced chemo doses to see if tumors shrink while causing fewer side effects. The goal is…

This study tests an experimental oral drug called STX-721 in people with advanced non-small cell lung cancer that has specific EGFR or HER2 gene mutations. The trial has three parts: first finding a safe dose, then confirming the best dose, and finally expanding to more participa…

This study tests a new drug called ANS02 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial has two phases: first, finding a safe dose, then checking if the drug shrinks tumors. About 294 participants will take ANS02 a…

This early-stage trial tests an experimental drug called KQB548 in people with advanced solid tumors (like pancreatic, colorectal, or lung cancer) that have a specific KRAS G12D mutation. The main goals are to find a safe dose and see if the drug can shrink tumors. About 78 parti…

This study tests a new experimental drug called mavrostobart (PT199) in people with advanced solid tumors, specifically non-small cell lung cancer and pancreatic cancer. The drug is given alone or combined with other cancer treatments. The goal is to find the safest dose and see …

This phase 2 trial tests whether the experimental drug SAR445877 can help control advanced non-small cell lung cancer in people whose tumors no longer respond to immunotherapy. About 29 adults with locally advanced or metastatic disease will receive the drug by IV. The main goal …

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This early-phase trial is testing a new drug called ASP5834 in people with advanced solid tumors that have certain changes in the KRAS gene. The study will first find a safe dose of ASP5834 given alone or with another drug (panitumumab) in people with colorectal cancer. Up to 364…

This study tests a combination of four drugs (JS212, JS207, Toripalimab, and JS213) in people with advanced lung cancer that has spread or come back. The goal is to see if the combination can shrink tumors and control the disease. About 864 participants will receive the drugs by …

This study tests whether the drug ivonescimab, given after standard radiation therapy (SBRT), can help prevent early-stage non-small cell lung cancer from returning. About 36 people with tumors up to 7 cm will receive the drug as a consolidation treatment. The main goal is to see…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This study tests a new drug called LBL-024 combined with other medicines in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or stop them from growing. About 230 adults aged 18-75 will take p…

This study tests a new treatment using a patient's own immune cells (called TILs) to prevent non-small cell lung cancer from returning after surgery. About 45 adults who have already had chemotherapy and surgery will be randomly assigned to receive either TILs plus standard care,…

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

This phase 3 trial is testing which sequence of EGFR-inhibitor drugs works best for people with advanced EGFR-mutated lung cancer. About 200 participants will receive either a second-generation drug (afatinib or dacomitinib) followed by a third-generation drug (osimertinib), or o…

This study is for people with a certain type of lung cancer (stage IIB-IIIB) that can be removed with surgery. Participants first get chemotherapy plus the immunotherapy drug durvalumab before surgery. After surgery, those whose cancer did not fully disappear are randomly assigne…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This study tests a new drug called HLX17, which is similar to the cancer drug Keytruda. It is for people who have had surgery for non-small cell lung cancer, melanoma, or kidney cancer. The goal is to see how the drug moves through the body, how safe it is, and how well it works …

This phase 2 trial is testing a new drug called SHR-1826 in 90 people with advanced non-small cell lung cancer that has worsened after other treatments. Participants receive the drug by IV every three weeks. The study aims to see if the drug can shrink tumors and how safe it is.

This early-stage trial is testing a new drug called IBI3028 in people with advanced solid tumors that cannot be removed by surgery or have spread. The drug works by attaching to two proteins (EGFR and c-Met) found on some cancer cells and delivering two anti-cancer agents directl…

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injecti…

This early-stage trial tests a new drug called BHV-1530 in about 95 adults whose solid tumors have spread or cannot be removed. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrinks tumors or slows the disea…

This early study tests a drug called TolueneSulfonamide, injected directly into the chest cavity, to see if it can safely reduce fluid buildup in people with lung cancer. About 105 participants will receive the drug three times a week for one week. The goal is to control the flui…

This study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…

This early-phase trial tests a new treatment made from specially engineered cord blood cells (TROP2-CAR-NK cells) in adults with advanced solid tumors that have not responded to standard therapies. The main goal is to find a safe dose and monitor side effects. Up to 54 participan…

This study tests a new combination of drugs (SKB264 plus KL-A167, with or without chemotherapy) in about 110 adults with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow cancer growth. Participants must h…

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib), can shrink tumors before surgery in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). About 60 adults aged 18-75 who have not had prio…

This early-phase trial is testing a new drug called PT0511, given alone or with cetuximab, in adults with advanced solid tumors that have a KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 195 par…

This early-stage study is testing an experimental drug called MK-6204 in about 90 adults with advanced solid tumors (such as colorectal, lung, or stomach cancer) that have not responded to standard therapies. The main goals are to check the drug's safety and find the right dose. …

This early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…

This study tests a new drug called SKB518 in 192 adults with lung cancer (non-small cell or small cell). The goal is to see if it shrinks tumors and to check for side effects. Participants receive the drug alone until their disease gets worse or side effects become too severe.

This study tests a new drug called sunvozertinib combined with chemotherapy in people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants must have already tried and failed an EGFR-targeted therapy. The goal is to see if the combination can shr…

This study looks at whether adding a precise radiation dose to liver tumors can make standard immunotherapy work better for people with stage IV non-small cell lung cancer. About 68 adults whose cancer has spread to the liver will either get standard drug therapy alone or standar…

This early-phase trial tests whether adding carotuximab to the standard drug osimertinib is safe for people with advanced EGFR-mutated non-small cell lung cancer. About 60 participants whose cancer has progressed on prior treatments will receive both drugs. The main goal is to fi…

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 420 adults who have not had prior treatment for advanced dis…

This early-stage trial tests an experimental drug called BBO-8520 in 350 people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The drug is taken as a pill and aims to block cancer growth. The study will check for safety, side effects, and…

This study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety, and will compare the combination to standard treatments like pembrolizuma…

This study tests whether giving high-precision radiation (SBRT) to the main tumor and nearby lymph nodes, along with standard chemotherapy, can better control stage III non-small cell lung cancer. The trial will enroll 20 adults whose tumors are less than 6 cm and who have not sp…

This phase 3 trial is testing whether adding an extra immunotherapy drug (tremelimumab) and more chemotherapy to the standard treatment (durvalumab) can lower the amount of cancer DNA found in the blood of people with stage III non-small cell lung cancer. The study enrolls 48 par…

This study tests a new drug called MDX2001 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety and see if it can shrink tumors. About 285 adults with various cancers like lung, breast, or colon cancer will take part. This is an ear…

This study tests a new drug called BL-B01D1 combined with an immunotherapy (PD-1 antibody) in people with advanced lung cancer, nasopharyngeal cancer, or other solid tumors that have spread. The goal is to see if the combination can shrink tumors and control the disease. About 57…

This phase 3 trial tests whether adding the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) to the standard pill osimertinib can better control advanced EGFR-mutated non-small cell lung cancer compared to osimertinib alone. About 582 adults with stage IIIB/IV or recurre…

This phase 2 trial is testing whether adding the antidepressant olanzapine to standard immunotherapy (nivolumab) helps people with advanced EGFR-negative non-small cell lung cancer live longer. About 156 participants will receive either the combination or immunotherapy alone for …

This study tests a new surgical technique called septum-guided segmentectomy for people with small, early-stage lung cancer located deep in the lung. The goal is to remove the cancer completely while saving as much healthy lung tissue as possible, which may help preserve breathin…

This early-phase study tests whether adding a short course of high-dose radiation before standard chemotherapy and immunotherapy can help shrink borderline resectable non-small cell lung cancer before surgery. About 18 adults with stage II to IIIC lung cancer will receive three d…

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with a specific type of advanced lung cancer (MET-positive non-squamous non-small cell lung cancer) live longer without their cancer growing. About 300 adults who have not had prio…

This study is testing a new way to give chemotherapy and immunotherapy for people with advanced lung or head and neck cancers. Instead of giving both treatments together every time, the plan alternates cycles of chemo plus immunotherapy with immunotherapy alone. The goal is to se…

This large Phase 3 trial is testing whether a new immunotherapy drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. The st…

This study tests a new drug called sutetinib in people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations (L861Q, G719X, or S768I). About 99 participants will take the drug by mouth to see if it shrinks tumors and how safe it is. The goal is to find…

This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases w…

This study tests a new drug called CKD-703 in people with advanced solid tumors or non-small cell lung cancer that has a specific protein (c-Met). The drug is designed to attach to cancer cells and release chemotherapy directly inside them, aiming to kill the cancer while reducin…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the dru…

This study tests a new drug called pumitamig (BNT327) combined with standard chemotherapy (docetaxel) in 60 people with advanced non-small cell lung cancer that got worse after initial treatment. The goal is to see if the combination is safe and shrinks tumors. It is an early-pha…

This study is testing an oral drug called sutetinib maleate in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors and control the disease. About 66 adults will take the drug and be monitored for respo…

This early-stage trial is testing a new type of targeted radiation therapy for people with advanced pancreatic, lung, breast, or colorectal cancers. The treatment uses a radioactive drug that seeks out cancer cells to deliver radiation directly, aiming to kill them while sparing …

This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…

This study tests a new daily pill, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The goal is to see if the drug is safe and can shrink tumors when used alone or with other cancer treatments. Ab…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This study tests a drug called 177Lu-FAP-2286, which delivers radiation directly to cancer cells. It is for people with advanced solid tumors (like pancreatic, lung, or breast cancer) that have a specific protein called FAP. The trial has two parts: Phase 1 finds the safest dose,…

This study tests whether combining the drug ivonescimab with either Dato-DXd or osimertinib is safe and effective for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC) that has stopped responding to previous treatments. About 66 participants will receive dif…

This study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific change in the SMARCA4 gene. The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 adults whose cancer has not responded to standar…

This study compares two treatments for people with advanced squamous non-small cell lung cancer who have not had prior therapy. Participants will receive either the experimental drug RC148 or the approved drug tislelizumab, both combined with chemotherapy. The goal is to see whic…

This Phase 3 trial tests whether adding Sigvotatug Vedotin to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high levels of PD-L1. About 714 participants will receive either the combinati…

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This phase 3 trial is testing whether adding an experimental IV drug called BL-B01D1 to the standard pill osimertinib works better than osimertinib alone for people with advanced EGFR-mutated non-small cell lung cancer. About 720 participants will be randomly assigned to one of t…

This study tests a new drug called ivonescimab, given with standard chemotherapy and focused radiation (SRS), for people with non-small cell lung cancer that has spread to the brain. The goal is to find the safest dose and see if it helps control the brain tumors. About 53 adults…

This study tests a two-part treatment for people with colorectal or non-small cell lung cancer that has spread to the liver and hasn't responded to standard therapies. The treatment combines a liver-directed procedure (TATE) that delivers a chemotherapy-like drug directly to the …

This study compares two treatments for early-stage lung cancer in patients who are high-risk for surgery: removing part of the lung (sublobar resection) versus precise, high-dose radiation (stereotactic ablative radiotherapy). About 272 participants will be randomly assigned to o…

This early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…

This phase 3 trial is testing whether adding an experimental drug called SHR-A2009 to the standard targeted therapy aumolertinib works better than aumolertinib alone for people with advanced non-small cell lung cancer that has an EGFR mutation. About 576 participants who have not…

This study tests whether adding targeted, high-dose radiation to standard drug therapy (chemotherapy or immunotherapy) helps people with non-small cell lung cancer that has spread to up to 5 spots live longer. About 240 participants will be randomly assigned to receive either sta…

This study tests whether two drugs, pembrolizumab and lenvatinib, can shrink brain tumors in people with breast cancer, lung cancer, or other solid tumors that have spread to the brain. About 87 participants will receive the combination therapy. The goal is to see how well the tr…

This early-stage trial tests a new drug called KIVU-107 in 76 adults with advanced solid tumors that have not responded to standard treatments. KIVU-107 is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to find a safe dose and check for side…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests a new drug, taletrectinib, against the current standard drug crizotinib in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletrec…

This early-stage study tests a new drug called VIR-5525, alone or with another cancer drug (pembrolizumab), in people with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. About 450 adults with tumors that cannot b…

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, …

This early study tests a new type of radiation surgery called hypervision proton surgery for people with early-stage non-small cell lung cancer. The goal is to see if a single, high-dose treatment is safe and can control the tumor. Only 12 participants will be enrolled, and resea…

This phase 3 trial is testing whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes 536 adults whose cancer worsened after prior immunotherapy. Participants are r…

This phase 3 trial tests whether adding metformin, a standard diabetes drug, to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 312 participants will receiv…

This study tests a combination of two drugs—lorlatinib (a daily pill) and ramucirumab (an IV infusion every three weeks)—in people with advanced ALK-rearranged non-small cell lung cancer. The first part finds the safest dose, and the second part checks if that dose helps keep the…

This study tests whether combining a targeted pill (adagrasib) with precise radiation (SRS) can control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C mutation). About 30 adults with untreated brain metastases will receive both treatments. The main…

This phase III trial tests whether adding nitroglycerin patches to standard radiation therapy helps shrink brain tumors better than radiation alone in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). 74 participants will receive either radiatio…

This phase 1 trial tests a personalized, accelerated radiation therapy for locally advanced lung cancer. The radiation dose is tailored to each patient's tumor size and location, aiming to deliver a higher dose in fewer sessions. The study will enroll 45 adults with non-small cel…

This phase 3 trial tests whether using MRI scans to guide radiation therapy can improve outcomes for people with locally advanced non-small cell lung cancer. Participants receive radiation, chemotherapy, and immunotherapy. The study compares MRI-guided radiation to standard CT-gu…

This early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This phase 2 trial is testing the immunotherapy drug pembrolizumab, given alone or with chemotherapy, in 318 Black patients with advanced non-small cell lung cancer. The goal is to see how well these treatments work in real-world settings and to find biological markers that predi…

This early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. …

This phase 2 trial is testing whether giving low-dose radiation along with two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink tumors in people with stage IB to III non-small cell lung cancer. About 25 participants will receive the combination, then have …

This early-stage trial is testing a new approach for people with advanced non-small cell lung cancer that has specific gene changes (EGFR, ALK, ROS1, or HER2). Doctors take immune cells from the patient's own tumor, boost them in the lab with a molecule called CD40L, and then giv…

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and two immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check saf…

This phase 2 trial tests fingolimod, a drug already used for multiple sclerosis, in 38 adults with advanced non-small cell or small cell lung cancer that worsened after chemo-immunotherapy. Participants take a 0.5 mg pill daily. The study first checks safety, then looks at whethe…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study is testing whether combining two drugs—Envafolimab (an immunotherapy injection) and Lenvatinib (a daily pill)—can shrink tumors in people with advanced solid cancers like lung, kidney, and liver cancer. About 170 adults whose cancer has worsened after standard treatmen…

This study tests whether adding the immunotherapy drug envafolimab to standard chemotherapy helps shrink tumors before surgery and delays cancer return in people with stage III non-small cell lung cancer. About 390 participants will receive either envafolimab plus chemo or a plac…

This study is testing whether a fecal transplant from a healthy donor, combined with the immunotherapy drug pembrolizumab, can help people with a certain type of advanced lung cancer (PD-L1 positive non-small cell lung cancer) that has not responded to previous treatments. The tr…

This study tests a new drug called andamertinib, alone or with chemotherapy, against standard chemotherapy in people with advanced non-squamous lung cancer that has unusual EGFR mutations. About 40 participants who have not had prior treatment will be enrolled. The goal is to see…

This study compares two treatments for small lung spots called ground-glass nodules: cryoablation (freezing the nodule) and thoracoscopic surgery (removing it). Researchers want to see which approach is safer and better at preventing the nodules from coming back. About 160 adults…

This early-phase trial tests a new drug called VVD-159642, which targets specific cancer-driving proteins. It is given alone or with other drugs (sotorasib or trametinib) to people with advanced solid tumors that have certain genetic changes. The main goals are to check safety, f…

This early-phase study tests a new drug, ASP1002, in adults with advanced solid tumors that have high levels of a protein called claudin 4. The main goals are to check the drug's safety, find the best dose, and see how well people tolerate it. Participants receive the drug throug…

This study tests whether applying a surgical sealant (Progel Platinum) to staple lines during lung cancer surgery can reduce the time patients need a chest tube. About 160 adults having minimally invasive lung lobectomy for non-small cell lung cancer will be randomly assigned to …

This study tests an experimental oral drug called FMC-376 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The trial has three parts: first, finding the safest dose; then, checking how well th…

This study tests a new drug called ABSK141 in people with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to find a safe dose and see if the drug can shrink tumors. About 401 adults with cancers like colorectal, lung, or pancreatic cancer will…

This study tests a new drug, telisotuzumab adizutecan, in people with advanced EGFR-mutated non-small cell lung cancer whose cancer has progressed after a third-generation targeted therapy. About 430 adults will receive either the new drug or standard care. The goal is to see if …

This study tests a new treatment for people with advanced non-small cell lung cancer that has not responded to standard therapies. The treatment uses specially engineered natural killer (NK) immune cells that target two cancer-related proteins on tumor cells. Participants receive…

This study tests whether adding a new drug (ivonescimab) to standard chemotherapy can help people with advanced non-small cell lung cancer who did well on initial immunotherapy but still have signs of cancer DNA in their blood. About 70 adults aged 18-75 will be randomly assigned…

This early-phase trial is testing a combination of two drugs—FC084CSA and tislelizumab—in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and see if the combo can control tumor growth. Only 33 participa…

This phase 2 trial tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The drug is given through an IV and aims to shrink tumors or stop them from growing. Researchers will check how well it works and mon…

This study tests whether adding a traditional Chinese herbal decoction (HGXJT) to standard immunotherapy can help control lung cancer that has spread to the bones. About 82 adults with a specific type of lung cancer (non-small cell, without certain gene mutations) will receive ei…

This early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…

This study tests a combination of two drugs, MCLA-129 and ensartinib, in people with advanced solid tumors that cannot be cured. The drugs work by blocking certain proteins that help cancer grow. The trial has two phases: first to find the safest dose, then to see if the combo sh…

This phase 2 study is testing stereotactic body radiation therapy (SBRT) for people with non-small cell lung cancer or other cancers that have spread to the lung. Instead of daily radiation for weeks, participants receive high doses in just 3 to 10 sessions over 1 to 2 weeks. The…

This study is testing a new drug called QL1706, which helps the immune system fight cancer, combined with standard chemotherapy before surgery for people with stage IIB-IIIB non-small cell lung cancer. About 30 participants will receive three cycles of the drug combo, then have s…

This phase 3 trial tests two oral drugs (IN10018 and D-1553) against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 400 participants who have not had prior treatment will be randomly assig…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest…

This phase II trial tests whether a drug called BIO 300, made from a soy compound, can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease. About 25 participants will receive BIO 300 along wi…

This study is for veterans with stage 3 non-small cell lung cancer that cannot be removed by surgery. It combines chemotherapy, immunotherapy, and radiation to see if this approach helps control the cancer longer and is safe. About 25 participants will receive the treatment, and …

This early-stage trial is testing a new daily pill called DZD6008 in 140 people with advanced non-small cell lung cancer that has certain EGFR mutations. The main goals are to check the drug's safety and see if it can shrink tumors. Participants will take DZD6008 by mouth every d…

This study tests whether adding low-dose radiation to the liver before standard immunotherapy can help people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive radiation before their first three immunotherapy cycles. The …

This study tests whether giving a very focused, high-dose radiation treatment (SBRT) to all visible cancer spots can delay the cancer from getting worse in people with breast or lung cancer that has spread to 1-5 places. About 145 participants will either receive standard care al…

This early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …

This study tests whether two experimental drugs (livmoniplimab and budigalimab) combined with chemotherapy work better than the current standard treatment (pembrolizumab plus chemo) for people with untreated metastatic non-squamous non-small cell lung cancer. About 840 adults wil…

This early-stage trial is testing a new drug called PRTH-101, alone or with an existing immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The study will enroll about 270 people and focus on safety, do…

This study is testing whether the drug trastuzumab deruxtecan can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated) before they have surgery. About 14 participants with stage II to IIIB non-small cell lung cancer will receive the drug an…

This phase 3 study compares ivonescimab, an experimental immunotherapy, to the standard drug pembrolizumab in 780 people with advanced non-small cell lung cancer that has high PD-L1 levels. Participants receive one of the two drugs as their first treatment. The study measures how…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This trial tests an experimental drug called CP-383 in people with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not responded to standard treatments. The drug is taken daily by mouth and works by blocking a process cancer cells need to grow. The study …

This study tests whether adding a third drug to standard immunotherapy (cemiplimab) plus chemotherapy works better for people with early-stage non-small cell lung cancer who can have surgery. About 120 adults will receive treatment before and after their operation. The main goal …

This Phase 2 trial tests the targeted drug lazertinib, alone or with chemotherapy, before surgery in 160 adults with EGFR-mutant non-small cell lung cancer (stages IB to IIIB). The goal is to see if these treatments can shrink tumors enough to improve surgical outcomes. Participa…

This study uses a blood test to detect tiny amounts of cancer DNA left after standard treatment for early-stage non-small cell lung cancer. People whose blood shows this leftover cancer are at higher risk of the cancer coming back. The study tests whether the drug durvalumab can …

This phase 2 trial tests whether using a proteomic test (PROphet CB) and a toxicity assessment (CARG-TT) to guide first-line treatment can improve 12-month survival in people with advanced non-small cell lung cancer. About 56 participants will be randomly assigned to receive eith…

This study looks at whether giving radiation to the chest after surgery and chemo-immunotherapy can help people with stage III non-small cell lung cancer who still have signs of cancer after treatment. About 118 adults will be randomly assigned to receive or not receive radiation…

This study is testing an experimental drug called MCLA-129 in people with advanced solid tumors, including non-small cell lung cancer, head and neck cancer, and colorectal cancer. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met)…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…

This study tests whether adding the experimental drug SKB264 to the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV disease w…

This program offers early access to telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved by local regula…

This early-phase study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells. The main goal is to fi…

This study tests whether a dye called indocyanine green (ICG) can help surgeons see the exact boundary of a lung cancer tumor during robotic surgery. The dye makes the healthy lung glow, leaving the cancerous segment dark. The surgeon then removes only that dark segment, sparing …

This study tests whether adding a hand-held breathing muscle trainer to standard pre-surgery exercise rehab can reduce complications and hospital stays for people with lung cancer. About 100 adults scheduled for lung cancer surgery will be split into two groups: one gets standard…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This study tests a combination of two drugs—tulmimetostat (an EZH2 inhibitor) and pembrolizumab (an immunotherapy)—in 66 veterans with advanced non-small cell lung cancer that has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow ca…

This early-stage trial is testing a new drug, BM230, in people with advanced solid tumors, especially those linked to HER2. The study has two parts: first, finding the safest dose, then expanding to see how well it works. About 123 participants will be enrolled worldwide.

This study is for people with a specific type of advanced lung cancer (ALK-positive) that has gotten worse during or after treatment with the drug lorlatinib. Researchers want to see if a different drug, iruplinalkib, can help control the cancer for a longer time. About 20 adults…

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants re…

This study tests two oral drugs, GEN-725 and Dositinib, together in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The trial has two phases: first to find safe doses, then to see if the combination shrinks tumors. About 110 participants will ta…

This early-phase trial is testing an experimental drug called SIM0610 in 260 adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Particip…

This early-phase trial is testing an experimental oral drug called OCT-598 in 51 adults with advanced solid tumors, including breast, lung, and prostate cancers. The study aims to find the safest dose and see if the drug works alone or with standard chemotherapy. It is too early …

This early-stage trial is testing a new drug called GNC-077, a multi-specific antibody, in 20 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the right dose, and see how the body processes…

This phase 2 trial tests a new drug called nelmastobart combined with the chemotherapy docetaxel in 62 people with advanced non-small cell lung cancer that no longer responds to platinum chemo or immunotherapy. The goal is to see if the combination can slow cancer growth and impr…

This study tests an experimental pill called WJ22096 in about 20 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants take the pill by m…

This early-phase trial tests whether adding Tumor Treating Fields (TTFields) — a device that delivers electric fields to the tumor — to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About …

This study tests a new combination of two drugs (trastuzumab deruxtecan and pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced non-small cell lung cancer that has high levels of HER2 and low PD-L1. About 686 adults will t…

This early-stage trial tests a new drug called SIBP-A17 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein called HER2 found on some cancer cells. The study aims to find the safest dose and understand how the drug works…

This study tests a new combination of two drugs—ZG005 (given by IV) and gecacitinib (taken as a pill)—in 50 adults with advanced non-small cell lung cancer that has not responded to prior PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. Partic…

This early-phase study tests a new drug called SIBP-A13 in 144 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors or slow their growth. Participants will re…

This study tests whether adding radiotherapy to immunotherapy after surgery can help people with a certain type of advanced lung cancer (stage III N2 non-small cell lung cancer) live longer without the cancer coming back. About 60 adults aged 18 to 75 who have had surgery and hav…

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This phase 2 trial is testing whether giving a combination of low-dose radiation, stereotactic body radiotherapy (SBRT), the immunotherapy drug tislelizumab, and standard chemotherapy before surgery can improve outcomes for people with stage II to III non-small cell lung cancer. …

This study tests two experimental drugs, DZD9008 and AZD4205, together in people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation) and has stopped responding to standard treatments. About 90 adults will take part to see if the combination is…

This study compares two types of minimally invasive surgery for early-stage non-small cell lung cancer: robot-assisted lobectomy (using the Da Vinci system) and video-assisted lobectomy. Over 1,100 participants will be randomly assigned to one of the two procedures. The main goal…

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded to a combination of osimertinib and chemotherapy. About 70 adults will receive local therapy and be followed to see how long …

This study tests a combination of furmonertinib (a targeted pill), chemotherapy injected into the spine, and precise radiation for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. The goal is to see if this approach can contr…

This study tests a daily pill called sunvozertinib in 34 people with advanced non-small cell lung cancer that has certain uncommon EGFR mutations and has not been treated before. The goal is to see if the drug can shrink tumors and how safe it is. Participants take either 200mg o…

This early-phase study tests a new drug called ASKC202, given alone or with another drug (ASK120067), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. A…

This study looks at whether a simple blood test that finds cancer DNA can help doctors decide who needs extra treatment after lung cancer surgery. About 66 people who had their lung cancer removed will either get chemo-immunotherapy or just be watched. The goal is to see if the b…

This phase 2 trial tests zanidatamab, a drug that targets cancer cells with a HER2 gene alteration, in 105 adults with advanced lung, endometrial, colorectal, head & neck, or sarcoma cancers. Participants receive the drug every 3 weeks, and doctors monitor tumor shrinkage and sid…

This study is for people with a type of advanced lung cancer (non-small cell) that cannot be treated with surgery or standard chemo-radiation. It tests adding experimental drugs that block DNA repair to standard radiation therapy, followed by a year of immunotherapy (durvalumab).…

This study tests a daily pill called sunvozertinib against a placebo in 360 people with a specific type of lung cancer (stage IB-IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can stop the cancer from returning. Participants must have certain EGF…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer whose tumors have certain gene changes (RET, ROS1, NTRK fusions or increased MET/AXL activity). The drug is taken by mouth and aims to shrink tumors and stop them from growing. About 86 part…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back i…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

This study tests a personalized vaccine called LK101, made from a patient's own tumor markers, combined with standard immunotherapy drugs (pembrolizumab, durvalumab, or tislelizumab) in 60 adults with advanced lung cancer. The goal is to see if the combination is safe and can hel…

This early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…

This study tests a new treatment called BioTTT001, a modified virus designed to attack cancer cells, in 42 adults with recurrent non-small cell lung cancer that has spread to the lining of the brain. The treatment is given through a small device placed in the head. The main goals…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This phase 2 study is testing a daily pill called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. The trial will enroll 18 adults who have not had prior treatment for their advanced cancer. Researcher…

This study tests a new drug called SHR-A2102 combined with other cancer treatments for people with a type of lung cancer that can be removed by surgery. The goal is to see if the combination can destroy more cancer cells before and after the operation, helping patients live longe…

This early-phase trial is testing an experimental drug called BL-M24D1 in 33 people with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tu…

This study tests whether anlotinib hydrochloride capsules can help prevent lung cancer from coming back in patients who still had cancer cells after surgery and chemotherapy. About 64 adults with stage IIA-IIIA non-small cell lung cancer will take the drug daily. The main goal is…

This phase 2 trial is testing TQB2102, a drug that combines an antibody with chemotherapy to specifically attack lung cancer cells that have HER2 gene abnormalities. The study will enroll 270 adults with advanced non-small cell lung cancer that cannot be surgically removed. Resea…

This study tests whether a higher dose of the targeted drug furmonertinib, either alone or combined with chemotherapy, can help people with advanced EGFR-mutant non-small cell lung cancer whose first targeted treatment stopped working. About 60 participants will be randomly assig…

This study tests whether adding electroacupuncture (a type of acupuncture with mild electric current) to standard immunotherapy can help control advanced non-small cell lung cancer in patients who are too weak for aggressive treatment. 120 participants will receive either real or…

This study tests a therapy using a patient's own tumor-infiltrating lymphocytes (TILs) to treat advanced non-small cell lung cancer. Doctors collect immune cells from a tumor, grow them in a lab, and infuse them back after mild chemotherapy. The goal is to see if this slows cance…

This study tests an experimental drug called TNG260 combined with an immunotherapy (pembrolizumab) in people with advanced solid tumors that have a specific gene change (STK11 mutation). The goal is to find the best dose and see if the combination is safe and can shrink tumors. A…

This study tests whether early heart monitoring and medication can prevent heart problems in people with advanced lung cancer receiving chemoradiotherapy and immunotherapy. About 524 participants will be randomly assigned to receive either standard care or additional heart-focuse…

This study tests whether using real-time adaptive radiation without the usual safety margin can reduce lung side effects in people with early-stage non-small cell lung cancer or limited lung metastases. About 130 participants will be randomly assigned to either standard radiation…

This study tests a new oral drug called dositinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation. The trial has two parts: first, finding the safest dose, then testing that dose in a larger group. Researchers will monitor side effects, how th…

This phase 2 trial tests whether using MRI-guided adaptive radiotherapy can safely eliminate extra safety margins around brain tumors, potentially reducing radiation-related brain damage. 168 adults with non-small cell lung cancer and 1-10 brain metastases will receive either the…

This study tests a drug called atezolizumab (Tecentriq) plus standard chemotherapy in 97 people with stage III non-small cell lung cancer. After initial treatment, some may have surgery, while others continue on atezolizumab. The goal is to see if this approach helps keep the can…

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced or metastatic solid tumors, including non-small cell lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults aged 18 to 75 who hav…

This early-stage study tests a new drug (tolododekin alfa) combined with an existing immunotherapy for people with advanced non-small cell lung cancer. The goal is to see if the combination can shrink tumors or slow disease progression. About 60 participants will join, including …

This study tests a new drug called SOA101, a special antibody that can attach to both cancer cells and immune cells to help the immune system attack tumors. It is for people with advanced solid tumors (like lung, ovarian, or breast cancer) who have no other standard treatment opt…

This study tests whether adding certolizumab (an anti-inflammatory drug) to standard chemotherapy and immunotherapy helps shrink stage II-III lung cancer more effectively before surgery. About 60 adults with operable lung cancer will receive the combination, then have their tumor…

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment will participate. The g…

This early-stage study tests a new drug called DAY301 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a powerful toxin directly to cancer cells while sparing healthy ones. The study aims to find the safest dose …

This study is testing whether adding an immune-boosting drug (BDB001) and targeted radiation to the immunotherapy atezolizumab can help control or shrink tumors in people with advanced solid tumors, including pancreatic, lung, bladder, and breast cancers. About 247 adults with th…

This study tests whether giving radiation to the main lung tumor before starting targeted therapy pills can delay cancer growth in people with advanced, gene-mutated non-small cell lung cancer. About 34 adults who have not yet had treatment will receive radiation to the primary l…

This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, t…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This phase 2 trial is testing a combination of three drugs—datopotamab deruxtecan, carboplatin, and pembrolizumab—in 46 people with non-small cell lung cancer that has spread to the brain and who have not had prior treatment for those brain tumors. The goal is to see how well the…

This study tests two experimental drugs, SI-B001 and SI-B003, given together with or without chemotherapy in 160 people with advanced non-small cell lung cancer. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. Participants must …

This phase II trial tests two drugs, SI-B003 and BL-B01D1, alone or together in 121 adults with advanced non-small cell lung cancer or nasopharyngeal carcinoma. The goal is to see if the combination shrinks tumors and to find the safest, most effective dose. Participants must hav…

This early-phase trial tests whether a capsule containing a healthy gut bacterium (EXL01) can boost the effectiveness of the immunotherapy drug nivolumab in people with advanced non-small cell lung cancer that has stopped responding to prior immunotherapy. The study will enroll 2…

This study tests whether adding an experimental drug (ES102) to an approved immunotherapy (toripalimab) can shrink tumors in people with advanced non-small cell lung cancer that has not responded to prior treatment. About 40 adults aged 18-75 will receive the combination and be m…

This study tests whether adding a special type of radiation (SFRT) to standard cancer treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults whose cancer has progressed in a limited number of spots will receive …

This study tests whether a lower dose of the targeted therapy osimertinib can control advanced EGFR-positive non-small cell lung cancer while reducing side effects. About 58 adults with this specific genetic type of lung cancer will receive 80 mg every other day. Researchers will…

This early-stage trial is testing a new drug called AOH1996 in 92 adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The drug works by blocking a protein that cancer cells need to grow. The main goals are to fi…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This phase II trial is for people with a specific type of non-small cell lung cancer that has spread to only a few places in the body (oligometastatic) and has a driver mutation like EGFR or ALK. Participants have already been on a targeted therapy pill (TKI) for 2-4 months witho…

This study tests a new drug called YL202 combined with other anti-cancer medicines (toripalimab or furmonertinib) in people with advanced solid tumors, including breast and lung cancer. The goal is to find safe doses and see if the combination shrinks tumors. About 414 adults age…

This early-stage trial is testing an experimental drug called LB1410, a bispecific antibody designed to block two immune checkpoints (PD-1 and TIM-3) and help the immune system fight cancer. It involves 100 adults with advanced solid tumors or lymphoma who have exhausted standard…

This study tests whether using a smartphone app (Fissios App) for breathing exercises, in addition to in-person physiotherapy, can reduce complications after lung cancer surgery. About 560 adults with non-small cell lung cancer scheduled for surgery will be randomly assigned to e…

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of the…

This study tests an experimental oral drug called WSD0922-FU in 40 adults with advanced non-small cell lung cancer that has a specific mutation (C797S) and has stopped responding to the standard treatment osimertinib. The main goal is to see if the drug can shrink tumors. It is a…

This phase 2 trial is testing whether combining the immunotherapy drug toripalimab with cryoablation (a procedure that freezes and kills tumor cells) can help control advanced non-small cell lung cancer that has started to grow again after initial treatment. The study enrolls 54 …

This early-phase study is testing two radioactive imaging agents, 68Ga-DFC413 and 68Ga-NNS309, to see how well they highlight tumors on PET scans. About 66 adults with advanced pancreatic, lung, breast, colorectal, or soft tissue cancers will receive the agents. The goal is to co…

This study enrolls 1000 people with untreated non-small cell lung cancer to compare different genetic tests for MET gene changes. Participants provide tumor samples for testing, and researchers check how well the tests agree. The goal is to improve diagnosis and guide treatment c…

This study is testing a blood test that looks for tumor DNA to see if it can more accurately tell whether a lung nodule found on a CT scan is cancer. About 590 people getting lung cancer screening will give blood samples and be followed for 3 years. The goal is to improve how we …

This phase II trial is testing a new radioactive imaging agent called 68GaNOTA-Anti-MMR VHH2. It is designed to attach to certain immune cells (macrophages) in non-small cell lung cancer tumors and make them visible on a PET scan. The study will involve 20 patients who are alread…

This early-phase trial tests a new radioactive imaging agent, [18F]DK222, in 6 people with non-small cell lung cancer or urothelial cancer. The agent is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the agent is s…

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study is testing whether a minimally invasive procedure called EBUS-TBNA is more accurate than standard CT/PET scans for checking if lung cancer has spread to lymph nodes in the chest. The goal is to better select patients for a precise type of radiation therapy (SBRT). Abou…

This study is testing whether a special microscope called confocal laser endomicroscopy (CLE) can help doctors identify non-small cell lung cancer in real time during a biopsy. About 70 adults with suspected lung tumors will undergo standard bronchoscopy with added CLE imaging. R…

This early study is testing a new imaging agent called FL-261 in 12 people with advanced cancers like lung, colorectal, or head & neck cancer. The agent targets a protein called c-MET that is often found on cancer cells. Researchers want to see if FL-261 scans can safely and accu…

This study is testing a new radioactive tracer called 68Ga-TOI-1 for PET scans in people with lung cancer or suspicious lung nodules. The tracer targets a protein (CDH3) found only on cancer cells, which may help doctors see tumors more clearly than current scans. About 80 partic…

This study tests whether a special PET/CT scan (FAPI-PET/CT) and a fluorescent dye can better predict how well lung cancer responds to pre-surgery therapy and help surgeons see tumors during operation. 200 adults with stage II-IIIB non-small cell lung cancer will receive the scan…

This study tests a new technology called an electronic nose (E-Nose) that analyzes chemicals in a person's breath. Researchers want to see if it can accurately measure how well lung cancer responds to treatment and if the cancer comes back. The study involves 60 adults with non-s…

This study is testing whether an artificial intelligence (AI) system can accurately identify different types of lung cancer by analyzing PET/CT scans and patient information like age, smoking history, and tumor markers. Researchers aim to improve how doctors distinguish between s…

This study is testing whether measuring telomeres (parts of your DNA) in a blood sample can help doctors diagnose lung cancer. Researchers will collect blood from 1,200 people, including those with lung cancer and healthy volunteers, to build a predictive algorithm. The goal is t…

This early-phase study is testing a special PET imaging agent called [89Zr]Zr-DFO-emapalumab to see if it can detect non-small cell lung cancer lesions and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imaging age…

This early-phase study is testing a new imaging agent called [68Ga]CBP8 to see if it can safely and accurately detect collagen buildup (scarring) in the lungs. Researchers will compare scans from healthy volunteers, lung cancer patients, and people with pulmonary fibrosis. The go…

This early-phase study is testing a new radioactive tracer for PET scans that may better detect non-small cell lung cancer that has spread to the brain. About 20 adults with this type of lung cancer and brain metastases will receive the tracer and undergo imaging. The goal is to …

This study tests a special PET probe called [68Ga]CBP8 to see if it can detect tissue damage caused by radiation therapy in people with lung or pancreatic cancer. About 72 participants will get a PET scan before and 3-6 months after radiation. The goal is to find early signs of r…

This study is testing a new way to screen for early lung cancer using a combination of breath analysis, blood tests, and CT scans. Researchers aim to reduce the high rate of false positives from CT scans alone. They will enroll 1,800 participants, including people with lung cance…

This study tests whether synthetic PET images, created from standard CT scans using artificial intelligence, can accurately diagnose and guide treatment for lung cancer. Researchers will enroll 10,000 people with non-small cell lung cancer to see if this new method matches the qu…

This study is testing whether a blood test can find tumor DNA in people with cancer. If successful, it could lead to a less invasive way to diagnose cancer compared to current methods like tissue biopsies. The study will enroll 40 adults with newly diagnosed breast, colorectal, l…

This trial tests whether giving the painkiller parecoxib before a CT-guided wire placement can reduce pain during lung nodule localization for surgery. About 150 adults with lung cancer scheduled for video-assisted thoracoscopic surgery will receive either parecoxib or a placebo …

This study tests whether a prehabilitation program that combines home and center-based exercise works as well as a center-only program for people about to have lung cancer surgery. 38 adults with non-small cell lung cancer will be randomly assigned to either 15 sessions at the ce…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests a new drug called JMT203 in people with lung, pancreatic, or colorectal cancer who are experiencing cachexia (severe weight loss and muscle wasting). The drug is an antibody that targets a protein linked to appetite loss. The trial will enroll about 307 participa…

This study tests a new way to plan radiation therapy for people with stage 3 lung cancer. The method uses CT ventilation imaging to identify and avoid the healthiest parts of the lungs during treatment. Researchers want to see if this approach helps patients maintain a better qua…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if exercising…

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watc…

This study tests a brief program called Pathways, designed to help people with advanced lung cancer set personal goals and improve their mental health and quality of life during treatment. About 234 participants will be randomly assigned to receive either the Pathways program or …

This study is testing whether a supervised exercise program is safe and doable for people with lung cancer who are undergoing radiation and chemotherapy. Ten participants will do aerobic, strength, and breathing exercises several times a week for 7-9 weeks. Researchers will track…

This study tests whether a smaller 16F chest drain causes less pain than the standard 24F drain after minimally invasive lung surgery. About 124 adults having a lung lobe or segment removed will be randomly assigned to one drain size. Pain levels while coughing will be measured o…

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

This study looks at whether 12 weeks of different exercise programs can help people with advanced lung cancer who are already receiving immunotherapy. The goal is to see if exercise is safe and doable, and if it can improve immune markers. About 30 adults with non-small cell lung…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study looks at whether pulmonary rehabilitation—a program of exercise and breathing techniques—can improve breathing, fatigue, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do an 8-week rehab program, while the othe…

This phase 3 trial tests whether a daily nutritional drink (Oral Impact®) can reduce severe throat and esophagus inflammation caused by chest radiation in lung cancer patients. About 121 adults with lung cancer who need radiation will drink two bottles a day during and for three …

This study tests whether 10 weeks of online singing training can reduce symptoms and improve physical function and quality of life in people who had surgery for non-small cell lung cancer 6 to 18 months ago. One hundred participants will be randomly assigned to either the singing…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This study compares how patients feel after two minimally invasive surgeries for early-stage lung cancer: segmentectomy (removing a small part of the lung) and lobectomy (removing a whole lobe). Researchers will track shortness of breath, physical function, and quality of life fo…

This study tests a mobile app called PROMOTE designed to help lung cancer survivors improve their physical function, manage shortness of breath and sleep problems, and adopt healthier habits. About 250 adults with early-stage lung cancer will either use the app for 12 weeks or re…

This study tests whether a special imaging method (4DCT) can help doctors avoid giving too much radiation to healthy, working parts of the lung during radiotherapy for lung cancer. About 100 adults with lung cancer will receive standard radiation, but their treatment plan will be…

This study tests a program called CARES that provides nurse navigators and counselors to rural cancer patients. The goal is to see if this support helps patients start and finish treatment more quickly and improves their quality of care. About 320 adults with solid tumors like lu…

This study tests a new way to remove small lung tumors using a 3D computer model and a dye that makes the tumor glow during surgery. The goal is to help surgeons remove only the diseased part of the lung, avoiding a full lobe removal. About 32 adults with early-stage lung cancer …

This study tests whether adding intravenous vitamin C to standard chemotherapy can improve quality of life for people with advanced non-small cell lung cancer. About 90 adults with incurable lung cancer will receive either vitamin C or a placebo alongside their usual treatment. T…

This study is testing whether a mobile app that guides users through yoga poses is practical and safe for people with lung cancer who are getting radiation therapy, and for their family caregivers. About 60 patient-caregiver pairs will try the app at home. The goal is to see if p…

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This study tests whether a nurse-led program that includes regular symptom check-ins, guidance, and exercise can improve survival and quality of life for 250 vulnerable lung cancer patients. Participants will be randomly assigned to receive this extra support or standard care. Th…

This study tests a 12-week home-based coaching program for people who had surgery for early-stage lung cancer. Participants wear a Fitbit and get personalized step goals and coach calls to help them move more. The goal is to see if this support improves daily physical activity co…

This study tests whether adding daily cycling to standard physical therapy helps people recover faster after minimally invasive lung cancer surgery. 184 participants will be randomly assigned to either standard rehab or standard rehab plus 20 minutes of stationary cycling. The ma…

This phase 3 trial tests whether a drug called nanocrystalline megestrol acetate can help people with advanced non-small cell lung cancer maintain their appetite and avoid significant weight loss while undergoing chemoradiotherapy. About 134 participants will receive either the d…

This study is looking for genetic clues that might tell doctors whether immunotherapy will work well before lung cancer surgery. Researchers will collect blood and tumor samples from 100 people with stage II-IIIB non-small cell lung cancer. They will test for two types of genetic…

This study collects tissue samples and health information from 2000 adults with certain lung and thymic cancers. Researchers aim to better understand these diseases, which could lead to new diagnostic tools and treatments. Participants provide blood, tumor samples, and imaging da…

This study collects blood and tumor tissue samples from people with head and neck or lung cancers to find biological markers that indicate low oxygen levels within tumors. Low-oxygen tumors tend to be more aggressive and resistant to standard treatments like radiation and chemoth…

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study observes 500 Spanish patients with EGFR-mutated non-small cell lung cancer who are taking osimertinib in routine care. It aims to measure survival, quality of life, and how long patients stay on treatment. The goal is to see if results from clinical trials hold up in r…

This study follows 500 European patients with advanced non-small cell lung cancer who are already prescribed cemiplimab (Libtayo) as part of their normal care. Researchers will track how long patients live, how well the cancer responds, and any side effects. The goal is to see if…

This study looks at fluid from around the lungs (pleural effusion) in people with non-small cell lung cancer. Researchers want to see how often important cancer markers like PD-L1, ALK, and EGFR can be found in that fluid. They will also check if the amount of fluid tested affect…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study uses surveys to understand what factors influence Chinese patients and doctors when selecting first-line EGFR-TKI therapy for advanced non-small cell lung cancer. Researchers will ask about preferences for treatment benefits, side effects, and other attributes. The goa…

This study is collecting information from 130 people with advanced EGFR-mutant non-small cell lung cancer who are starting treatment with osimertinib. Researchers want to see how long the drug controls the cancer in real-world settings, outside of strict clinical trial conditions…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This study is collecting information from 650 people with advanced lung cancer to create 'control arms' — groups that help researchers compare how well new treatments work. Participants will receive standard therapies, and their outcomes will be tracked. The goal is to make futur…

This pilot study explores whether eating high-fermented foods (like yogurt and kimchi) followed by high-fiber supplements can change the gut microbiome and improve immune response in people with melanoma or lung cancer who are receiving standard immunotherapy. Researchers will tr…

This study is testing whether a liquid biopsy (a blood test that looks for cancer DNA) can find tiny amounts of leftover cancer in people who have had surgery for early-stage non-small cell lung cancer. The goal is to see if this test can predict which patients might have their c…

This study is testing whether a special MRI scan using an inhaled gas called hyperpolarized xenon-129 can help doctors identify and predict lung damage caused by radiation therapy in lung cancer patients. The gas is breathed in instead of being injected like a typical contrast dy…

This study looks at how the body's metabolism might influence whether immunotherapy drugs work in people with non-small cell lung cancer. Researchers will collect and analyze tissue samples from 150 patients to compare those who respond to treatment with those who don't. The goal…

This study is testing whether a 12-week home-based walking program can change the immune system in people with lung cancer. Fifty patients will either do moderate continuous walking, high-intensity interval walking, or receive standard exercise advice. Researchers will measure ch…

This study tests whether an artificial intelligence (AI) model can help doctors make better treatment decisions for non-small cell lung cancer (NSCLC). About 300 patients will have their treatment plans created by both a standard team of doctors and the AI. Researchers will compa…

This study uses lab-grown tumor samples from 5 lung cancer patients to test whether natural compounds (resveratrol and artichoke extract) can make immunotherapy work better and cause fewer side effects. The goal is to find better drug combinations, not to cure the disease directl…

This study looks at whether adding febuxostat (a gout medicine) to the standard lung cancer drug osimertinib can increase the amount of osimertinib that reaches the brain. It involves 7 adults with a specific type of advanced lung cancer who are already taking osimertinib. Resear…

This observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…

This study is testing whether special PET scans can predict early on if immunotherapy (with or without chemotherapy) is working in people with advanced non-small cell lung cancer. Researchers will scan 200 patients before treatment, then at 6 and 12 weeks, looking for signs that …

This study is collecting blood and tumor samples from 200 people with non-small cell lung cancer to find biological markers that predict whether immunotherapy will work. Researchers will compare samples taken before treatment and at the time the disease gets worse. The goal is to…

This study is testing a new technology that uses x-rays to track lung tumors during radiation therapy, without needing to implant markers in the lung. About 30 people with early-stage lung cancer or a few lung metastases will take part. The goal is to see if the markerless tracki…

This pilot study tests whether using CT ventilation imaging can more accurately predict lung function after lung cancer surgery compared to the standard method. Researchers will compare predictions from CT scans with actual lung function tests in 15 surgical candidates. If succes…

This study tests whether special X-ray imaging techniques can map which parts of the lung are working best, so radiation for lung cancer can avoid those areas. Fifteen adults with stage II-IV lung cancer will get extra scans before and after their standard radiation treatment. Th…

This study tests a new way to predict how well your lungs will work after lung cancer surgery. Doctors will use 3D CT scans to create a virtual model of your lungs and simulate the surgery beforehand. The goal is to see if this method is more accurate than current techniques, hel…

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will re…

This study uses machine learning to analyze real-world data from over 144,000 people with advanced non-small cell lung cancer. The goal is to find which existing treatments work best for different patient groups, helping doctors make more personalized choices. Participants' healt…

This study is testing a software tool that uses DNA from a blood sample to predict the risk of blood clots returning in people with cancer who have finished 3-12 months of blood thinner treatment. The goal is to see if a low-risk result means it's safe to stop blood thinners with…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This observational study follows 100 adults with metastatic non-small cell lung cancer who have certain EGFR gene mutations and are receiving amivantamab plus platinum-based chemotherapy through an early access program. Researchers will collect medical data to see how long the tr…

This study looks at the biological features of a specific type of lung cancer (ALK-positive) in 100 patients. Researchers will analyze tumor samples and blood tests taken at diagnosis and when the disease worsens. The goal is to learn why some treatments stop working, not to test…

This study looks at how adults aged 70 and older with non-small cell lung cancer are treated in everyday medical practice. Researchers will track 500 participants to understand which treatments work best, how safe they are, and how they affect quality of life. The goal is to gath…

This study looks at why amivantamab, a drug for advanced non-small cell lung cancer with a specific EGFR mutation, stops working over time. Researchers will collect blood and tumor samples from 30 patients when their disease gets worse. The goal is to find genetic changes that ca…

This study is creating a large database of 10,000 lung cancer patients who received radiation therapy. Researchers will collect information on tumor control, side effects, and quality of life to build models that predict outcomes. The goal is to use these models to select the bes…

This study looks at whether DNA from blood, sputum, lung fluid, and breath can help find genetic changes in non-small cell lung cancer. Researchers will collect samples from 210 patients before and after surgery, then follow them for 24 months to check for cancer return. The goal…

This large clinical trial is testing whether the type of anesthesia used during lung cancer surgery affects the chances of the cancer coming back. Over 5,000 people having surgery for early-stage non-small cell lung cancer will be randomly assigned to receive either intravenous p…

This study enrolls 75 lung cancer patients under age 50 to see if a dedicated care program improves their satisfaction and well-being. Participants fill out surveys over five years about their needs, quality of life, and experience with peer support. The goal is to understand wha…

This pilot study will test whether lung cancer patients can use an Apple Watch, a home pulse oximeter, and a smartphone to collect health data during proton beam radiotherapy. About 40 participants will wear the devices from the start of treatment until two weeks after it ends. T…

This study is for people with early-stage lung cancer whose cancer returned after taking the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand why some cancers come back, which could h…

This study aims to understand the genetic makeup of non-small-cell lung cancer in 550 Taiwanese patients, especially those whose tumors are resistant to standard treatments. By analyzing tumor samples, researchers hope to find new drug targets and improve survival. Participants a…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This study is observing 300 adults with kidney, bladder, lung, or liver cancer who are starting immunotherapy (PD-1/PDL-1 inhibitors). Researchers will measure a protein called Galectin-3 in the blood before each treatment to see if its level is linked to how well the therapy wor…

This observational study looks at 300 people with early-stage lung cancer to understand why different types of the disease behave differently. Researchers will analyze genes, immune cells, and other markers from tumor samples. The goal is to find patterns that could lead to bette…

This study is tracking 100 people with early-stage lung cancer who had surgery. Researchers will measure tumor cells and DNA in their blood to see if these markers can predict if the cancer comes back. The goal is to better understand how lung cancer spreads and improve long-term…

This study is testing whether a simple rectal mucus sample can detect DNA changes linked to lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device and analyze them for genetic and epigenetic markers. The goal is …

This study tests a standardized technique for finding lymph nodes in lung tissue removed during surgery. Researchers want to see if this method finds more nodes and improves cancer staging. About 160 adults with lung cancer who are having a lobectomy will take part. The goal is t…

This study looks at whether advanced blood tests and artificial intelligence can help detect lung cancer recurrence earlier and without invasive procedures. About 100 adults who had surgery for stage IB-IIIA lung cancer and received standard chemo-immunotherapy before surgery wil…

This study looks at why some lung cancer cells survive targeted treatment. Researchers will take small tissue samples (biopsies) from 100 patients before and two weeks after starting therapy. By comparing the samples, they hope to find early signs of resistance and identify ways …

This study reviews medical records of 150 patients with inoperable lung cancer that returned after previous radiation. Researchers want to learn if giving another round of high-precision radiation (SBRT) is safe and effective. The goal is to help doctors make better treatment dec…

This study is collecting blood samples and health information from 1200 people with non-small cell lung cancer. Researchers want to understand how the cancer changes over time and whether simple blood tests can predict if the cancer will come back. Participants continue their nor…

This pilot study is looking at the gut microbiome—the collection of bacteria in your digestive system—in people with advanced non-small cell lung cancer. Researchers will collect stool and saliva samples before and during standard cancer treatment to see if the diversity of gut b…

This study aims to understand cancer-related fatigue in people with non-small cell lung cancer who are receiving immunotherapy. Researchers will interview 20 patients about their fatigue, daily function, and views on physical activity. The goal is to learn how fatigue affects pat…

This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also ch…

This study looks at whether a lab-grown model of a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions with how the patient actually responds to treatment. The goal is to see if this approach can guide…

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study is looking at whether regularly checking the amount of pembrolizumab in the blood of people with non-small cell lung cancer can help doctors tailor treatment. The goal is to see if this monitoring can improve how well the drug works and reduce side effects. The trial w…

This study looks at 400 lung cancer patients who had chemotherapy or immunotherapy before surgery. Researchers compare two surgical techniques: minimally invasive (using small cuts and a camera) versus traditional open chest surgery. The goal is to see which approach leads to bet…

This study is for people aged 70 and older with early-stage lung cancer who are scheduled for surgery. Researchers want to see if markers of aging (like changes in DNA and cell health) can help predict who will have complications or need unplanned hospital stays. The goal is to u…

This study looks at 48 adults with advanced lung cancer who are about to start immunotherapy. Researchers will collect samples from the lungs, stool, and blood before and after treatment to see if certain bacteria are linked to better outcomes. The goal is to understand why some …

This study is building a large database of blood samples, tumor samples, and scans from 4,000 people with lung cancer. Researchers will follow participants for up to 10 years to collect information that can help future studies. The goal is to better understand lung cancer and imp…

This study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This observational study aims to understand how ROS1-positive non-small cell lung cancer develops resistance to the drug entrectinib. Researchers will analyze blood and tissue samples from 38 patients who have already taken entrectinib as part of their regular care. By looking at…

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…

This study looks at whether asking patients with advanced lung cancer to fill out regular questionnaires about their quality of life, symptoms, and mental health can help doctors understand which treatment works best. About 144 people will complete online surveys before, during, …

This study collects tumor samples from 50 lung cancer patients whose disease has worsened while on immunotherapy. The goal is to analyze the tissue for clues about why the treatment stopped working. No new drug is being tested; instead, researchers hope to better understand resis…

This study tests whether dynamic MRI can better track lung tumor movement during breathing compared to standard CT scans. 150 patients receiving stereotactic body radiotherapy for lung tumors will get an extra MRI scan. If MRI proves more accurate, it could help doctors plan radi…